The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom.

Berdud, Mikel; Wallin-Bernhardsson, Niklas; Zamora, Bernarda; Lindgren, Peter; Towse, Adrian

Berdud, Mikel; Wallin-Bernhardsson, Niklas; Zamora, Bernarda; Lindgren, Peter; Towse, Adrian.

Afiliación

Berdud M; Office of Health Economics, London, England, UK. Electronic address: mberdud@ohe.org.
Wallin-Bernhardsson N; GlobalData, London, England, UK.
Zamora B; Imperial College, London, England, UK.
Lindgren P; Institute for Health Economics, Stockholm, Sweden.
Towse A; Office of Health Economics, London, England, UK.

Value Health ; 26(3): 328-335, 2023 03.

Article en En | MEDLINE | ID: mdl-36738786

Asunto(s)

Antipsicóticos; Risperidona; Humanos; Antipsicóticos/uso terapéutico; Análisis Costo-Beneficio; Haloperidol; Risperidona/uso terapéutico; Suecia; Reino Unido

Palabras clave

antipsychotics; consumer surplus; cost-effectiveness; generic competition; life cycle value; net monetary benefit; on-patent competition; producer surplus

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antipsicóticos / Risperidona Tipo de estudio: Health_economic_evaluation / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google